Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of BG00012 (dimethyl fumarate) in pediatric RRMS (extension of 109MS202)
2015-003282-29Phase 3Completed
- Sponsor
- Biogen
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dimethyl fumarate in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Adverse events and serious adverse events. Started Feb 2016; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-003282-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003282-29.